Psilocybin shows moderate efficacy in depression treatment but faces bias and conflict issues.
Psilocybin shows moderate efficacy in depression treatment but faces bias and conflict issues.
Why it matters
- Psilocybin may offer a new approach to treating depression but faces methodological and ethical challenges.
By the numbers
- 9 RCTs with 602 participants showed psilocybin was moderately superior to controls (effect size g=0.62).
- High heterogeneity and risk of bias noted in studies.
The big picture
- Psilocybin shows potential but needs more rigorous, independent studies.
What they're saying
- Concerns about financial conflicts of interest and funding for independent research.
Caveats
- High risk of bias and financial conflicts of interest in most studies.
- Study quality and independence need improvement.
What’s next
- Larger, well-controlled studies with independent funding are needed.